Sugi Predict

Sugi Predict / Compounds / SCHEMBL1025947

SCHEMBL1025947

SCHEMBL1025947

O=[N+]([O-])c1cccc(OCCBr)c1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CHRNB2 P17787 2/20 0.66
▸ CHRNA4 P43681 2/20 0.66
▸ LMNA P02545 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ LTA4H P09960 1/20 0.51
▸ PTGS2 P35354 1/20 0.51
▸ HPGD P15428 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ CHRNB4 P30926 1/20 0.49
▸ CHRNA3 P32297 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ MAPT P10636 1/20 0.48
▸ GRM5 P41594 1/20 0.47
▸ MAOB P27338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29739568 1.00 CHRNB2 (0.66) CHRNB2CHRNA4LMNATSHRLTA4H
SCHEMBL3720227 0.92 CHRNB2 (0.64) CHRNB2CHRNA4LMNATSHRLTA4H
SCHEMBL1171960 0.90 CHRNB2 (0.62) CHRNB2CHRNA4LMNATSHRLTA4H
SCHEMBL15498199 0.90 CHRNB2 (0.73) CHRNB2CHRNA4LMNATSHRLTA4H
SCHEMBL4343723 0.89 CHRNB2 (0.61) CHRNB2CHRNA4LMNATSHRLTA4H
SCHEMBL2483461 0.86 CHRNB2 (0.60) CHRNB2CHRNA4LMNATSHRALDH1A1
SCHEMBL14028449 0.86 CHRNB2 (0.69) CHRNB2CHRNA4LMNATSHRLTA4H
SCHEMBL73974 0.83 CHRNB2 (0.66) CHRNB2CHRNA4LMNATSHRLTA4H
SCHEMBL3442965 0.83 CHRNB2 (0.66) CHRNB2CHRNA4LMNATSHRLTA4H
SCHEMBL2374109 0.83 CHRNB2 (0.70) CHRNB2CHRNA4LMNATSHRLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391663-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS AG (CH) 2025-08-19 — — US disclosed
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2024-08-08 — — US disclosed
EP-4157844-B1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER CENTRE NAT RECH SCIENT (FR) 2024-07-10 — — EP disclosed
US-20240083869-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2024-03-14 — — US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
CN-117242060-A Isoindolinone compounds 蒙特罗萨医疗公司 2023-12-15 — — CN disclosed
EP-4278014-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 — — EP disclosed
EP-4277901-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 — — EP disclosed
US-20230348418-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2023-11-02 — — US disclosed
US-20230312576-A1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITÉ DE TOURS (FR) 2023-10-05 — — US disclosed
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 — — EP disclosed
WO-2002059080-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2002-08-01 — — WO disclosed
WO-2001097786-A2 BENZOTHIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-12-27 — — WO disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 — — WO disclosed
EP-0245997-B1 N-SUBSTITUTED P-AMINOETHYLSULPHON ANILIDES AS ANTIARRHYTHMIC AGENTS, AND INTERMEDIATES THEREFOR Pfizer Limited (GB) 1992-04-15 — — EP disclosed
US-5079248-A Antifibrillatory agents; side effect reduction PFIZER INC. (US) 1992-01-07 — — US disclosed
US-5006561-A Indane sulfonamide anti-arrhythmic agents and use PFIZER INC. (US) 1991-04-09 — — US disclosed
US-4959366-A Anti-arrhythmic agents PFIZER INC. (US) 1990-09-25 — — US disclosed
EP-0286278-A1 Indanamine derivatives useful as antiarrhythmic agents Pfizer Limited (GB) 1988-10-12 — — EP disclosed
EP-0245997-A2 N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor Pfizer Limited (GB) 1987-11-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391663-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 CHRNB2 236/4885CHRNA4 852/4885LMNA 1164/4885
US-20240083869-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 CHRNB2 236/4885CHRNA4 852/4885LMNA 1164/4885
US-20230348418-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 CHRNB2 232/4885CHRNA4 873/4885LMNA 1259/4885
US-11912682-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 CHRNB2 236/4885CHRNA4 852/4885LMNA 1164/4885
US-20240261274-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MYC, MYCBP, GSPT1 CHRNB2 4512/4885CHRNA4 4713/4885LMNA 3911/4885
US-20230312576-A1 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER LIMK1, LIMK2, ROCK1 CHRNB2 1201/4885CHRNA4 1417/4885LMNA 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.